Okay, so that is the same drug.
A 2015 article in The Globe and Mail said this:
Canadians with atypical hemolytic uremic syndrome (aHUS), a life-threatening genetic disease that damages vital organs and affects fewer than 100 people in the country, often require treatment with the drug Soliris at a hefty price tag of more than $700,000 a year. The cost spurred the federal Patented Medicines Price Review Board to call a public hearing into why the manufacturer, Alexion Pharmaceuticals, charges more in Canada than in other developed countries
Do you have any information to share with this committee on the outcome of that PMPRB hearing? Did they determine that the price of Soliris is excessive?